CounterX Therapeutics

Executive Summary

CounterX Therapeutics is a preclinical-stage biopharmaceutical company headquartered in Cambridge, MA, dedicated to ending the opioid overdose and addiction epidemic. Founded in 2021, the company exploits small molecules and vaccine approaches to develop novel therapies that address both overdose reversal and addiction treatment. By targeting the underlying mechanisms of opioid use disorder, CounterX aims to offer hope to individuals, families, and communities devastated by this crisis. As a private entity with no disclosed funding or valuation, the company remains in early research and development, with no publicly reported pipeline candidates. Its focus on dual modalities—small molecules for acute intervention and vaccines for long-term prevention—positions it at the forefront of a growing effort to combat opioid-related deaths, which continue to rise despite existing interventions. However, given its preclinical stage and lack of publicly available data, the company carries high scientific and execution risk. Success will depend on advancing its platforms through preclinical validation, securing partnerships or funding, and ultimately generating clinical proof-of-concept. The opioid crisis represents a large unmet medical need, providing significant market opportunity if the company's candidates prove safe and effective.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for lead vaccine candidate30% success
• TBDSeries A financing or strategic partnership announcement40% success
• TBDIND-enabling studies initiation for lead small molecule program25% success